Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.

This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that the Company's proprietary MITOLINE® algorithm platform can power a drug discovery and development progression in a target class that has historically been difficult to drug. MITOLINE® - the U.S. trademark-registered algorithm whose registration was announced by Nexentis in May 2026 enabled the identification of the program's initial hit molecule by generating reliable 3D structural models of a mitochondrial carrier protein in the SLC25 family, overcoming a central bottleneck in mitochondrial drug discovery: the near-total absence of experimentally solved 3D structures for this important protein class. The initial hit was identified by MITOLINE®-enabled virtual screenings and has now undergone systematic medicinal chemistry optimization, culminating in the generation of an optimized hit molecule that demonstrates clear improvements across key pharmaceutical parameters assessed as of March 31, 2026.

MitoCareX's program is advancing a novel small molecule drug candidate targeting a mitochondrial SLC25 carrier protein, developed to potentially address hard-to-treat cancers and inflammatory metabolic diseases. Oncology and inflammatory disease together represent one of the most dynamic and capital-intensive spaces in global pharma - with the cancer therapy market alone projected to grow from approximately $270 billion in 2026 to nearly $447 billion by 2031 (CAGR ~10.6%, Mordor Intelligence) and the anti-inflammatory drugs market projected to grow from approximately $129 billion in 2026 to $185 billion by 2031 , growing at CAGR ~7.5% (Mordor Intelligence). Within these markets, there remains a significant unmet need for novel, orally available small molecule therapies - the modality at the core of MitoCareX's discovery engine.